(Q24201686)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Interval debulking surgery for advanced epithelial ovarian cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

19 March 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Meta-analysis in clinical trials

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

First-line therapy in ovarian cancer trials.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Surgery in the treatment concept of epithelial ovarian cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Pretherapeutic scalene lymph node biopsy in ovarian cancer.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

[Primary treatment of ovarian cancer]

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

[Treatment of stage III and IV ovarian cancer--is neoadjuvant chemotherapy effective?].

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050358

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

29 November 2018

1 reference

12 December 2020

The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment

1 reference

12 December 2020

[Intra-arterial chemotherapy in advanced ovarian cancers. 2. Therapeutic results in relation to prognostic factors]

1 reference

12 December 2020

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

1 reference

12 December 2020

Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma

1 reference

12 December 2020

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer

1 reference

12 December 2020

Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

1 reference

12 December 2020

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

12 December 2020

[Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer]

1 reference

12 December 2020

Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206

1 reference

12 December 2020

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

1 reference

12 December 2020

Is the easier way ever the better way?

1 reference

12 December 2020

Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer

1 reference

12 December 2020

Intervention debulking surgery in advanced epithelial ovarian cancer

1 reference

12 December 2020

Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma

1 reference

12 December 2020

Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma

1 reference

12 December 2020

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

1 reference

12 December 2020

The potential role of neoadjuvant chemotherapy in advanced ovarian cancer

1 reference

12 December 2020

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602

1 reference

12 December 2020

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

1 reference

12 December 2020

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

1 reference

12 December 2020

Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study

1 reference

12 December 2020

A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer

1 reference

12 December 2020

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

1 reference

12 December 2020

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

1 reference

12 December 2020

[Treatment outcomes for advanced ovarian cancers with peritoneal dissemination]

1 reference

12 December 2020

Timing of surgery and the role of cytoreductive chemotherapy in patients with advanced ovarian carcinoma

1 reference

12 December 2020

Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery

1 reference

12 December 2020

Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma

1 reference

12 December 2020

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

12 December 2020

A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary

1 reference

12 December 2020

Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer

1 reference

12 December 2020

Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients

1 reference

12 December 2020

Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy--preliminary results

1 reference

12 December 2020

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

1 reference

12 December 2020

Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer

1 reference

12 December 2020

Neoadjuvant chemotherapy in advanced ovarian cancer

1 reference

12 December 2020

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists

1 reference

12 December 2020

Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study

1 reference

12 December 2020

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

12 December 2020

Neoadjuvant chemotherapy in stage X ovarian carcinoma

1 reference

12 December 2020

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial

1 reference

12 December 2020

Neoadjuvant chemotherapy for advanced ovarian cancer

1 reference

12 December 2020

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005343.PUB3

7 January 2021